Blog
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics
Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the me
…
17th Dec 2025
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements
Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like
…
17th Dec 2025
Indusatumab: Advancing Anti-CD47 Cancer Research with Biosimilar Innovations
Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does
…
8th Feb 2025
Crizanlizumab: A Comprehensive Overview of Its Role in Sickle Cell Disease and Ongoing Research
Quick Facts About CrizanlizumabWhat is Crizanlizumab?Crizanlizumab is a monoclonal antibody used to treat sickle cell disease by targeting P-selectin, a protein involved in inflammation
…
7th Feb 2025
Unveiling Prezalumab: Targeting the Role of Anti-CD47 in Cancer Immunotherapy
What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detect
…
6th Feb 2025
Alsevalimab: Targeting CD47 for Cancer Research and Treatment
Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
…
6th Feb 2025
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements
Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By
…
6th Feb 2025
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy
Quick Facts About ZilovertamabWhat is Zilovertamab?Zilovertamab is a monoclonal antibody targeting ROR1, a receptor tyrosine kinase overexpressed in hematologic cancers and solid tumors.
…
6th Feb 2025
Rovalpituzumab Tesirine: Advancing Small Cell Lung Cancer Research
Quick Facts About Rovalpituzumab TesirineWhat is Rovalpituzumab Tesirine?Rovalpituzumab Tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed to target DLL3, a protein overexpre
…
6th Feb 2025
Trastuzumab: Revolutionizing HER2-Positive Cancer Treatment & Research
Quick Facts About TrastuzumabWhat is Trastuzumab?Trastuzumab is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2 protein, re
…
6th Feb 2025
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy
Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
…
6th Feb 2025
Avdoralimab: Exploring Its Role in Immunotherapy and Biosimilar Advancements
Quick Facts About AvdoralimabWhat is Avdoralimab?Avdoralimab is a monoclonal antibody targeting C5aR1, playing a crucial role in modulating immune response and inflammation.What is the m
…
5th Feb 2025
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research
Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
…
4th Feb 2025
Natalizumab: Mechanism, Applications, and Emerging Research in Multiple Sclerosis and Crohn's Disease
Quick Facts About NatalizumabWhat is Natalizumab?Natalizumab is a monoclonal antibody used to treat multiple sclerosis (MS) and Crohn's disease. It works by blocking immune cells from at
…
2nd Feb 2025
Denosumab: A Comprehensive Overview of Mechanism, Applications, and Research Advances
What You Need to Know About DenosumabWhat is Denosumab?Denosumab is a monoclonal antibody used primarily to treat osteoporosis and bone-related complications in cancer patients. It targe
…
2nd Feb 2025
Talquetamab: Exploring its Role in Cancer Therapy and Ongoing Research
Quick Info Section: Key Facts About TalquetamabWhat is Talquetamab?Talquetamab is a novel monoclonal antibody being developed for the treatment of multiple myeloma and other cancers. It
…
2nd Feb 2025
Ivuxolimab: Redefining Cancer Immunotherapy and Research
Quick Facts About IvuxolimabWhat is ivuxolimab?Ivuxolimab is a monoclonal antibody targeting CD47, a "don't eat me" signal that cancer cells exploit to evade immune destruction.How does
…
1st Feb 2025
Dupilumab: Transforming Immunotherapy and Skin Disease Management
What You Need to Know About DupilumabWhat is Dupilumab?Dupilumab is a fully human monoclonal antibody designed to treat various chronic inflammatory diseases by inhibiting key cytokines
…
1st Feb 2025
Inebilizumab: Advancing Research and Clinical Applications
What You Need to Know About InebilizumabWhat is Inebilizumab?Inebilizumab is a humanized monoclonal antibody that targets CD19, a protein expressed on B cells, to treat autoimmune diseas
…
1st Feb 2025
Naratuximab: Redefining Cancer Therapy with Precision Medicine
Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym
…
1st Feb 2025
Ramucirumab: Mechanism, Clinical Applications, and Biosimilars in Cancer Research
Quick Facts About RamucirumabWhat is Ramucirumab?Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting angiogenesis, a pro
…
31st Jan 2025
Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy
What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c
…
31st Jan 2025
Icatolimab: Revolutionizing the Fight Against Cancer via CD47 Targeting
Quick Facts About IcatolimabWhat is Icatolimab?Icatolimab is a monoclonal antibody designed to target CD47, a protein that cancer cells use to evade immune detection.How does Icatolimab
…
31st Jan 2025
Ponsegromab: A Breakthrough in Heart Failure and Cachexia Research
Quick Facts About PonsegromabWhat is Ponsegromab?Ponsegromab is an investigational monoclonal antibody developed by Pfizer, primarily studied for its potential in treating heart failure
…
29th Jan 2025